Acute respiratory infections (ARIs) â€“ such as influenza, pneumonia and respiratory syncytial virus (RSV) â€“ cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).
Pneumonia & Flu
GAVI Says Pentavalent Vaccine Price To Fall, But $3.7B Still Needed To Vaccinate Children In Developing Countries
The average price of a vaccine that protects children against five diseases is expected to “drop to $2.58 next year compared to the current average price of $2.97,” the GAVI Alliance said Friday, Reuters reports. The group credits the expected price decline, which “represents a decrease of 30 percent over the last seven years,” in part to an “increased demand for the pentavalent, or five-in-one vaccine,” according to the news service (Kelland, 11/26).
Education for women is the most important factor for positively influencing the health of women and children, Indian President Pratibha Patil said on Saturday at a meeting in New Delhi of The Partnership for Maternal, Newborn & Child Health (PMNCH), IANS/Sify News reports. “Education is a powerful driver of health. The relationship between poverty, lack of education and limited access to health services, is well recognised,” Patil said at the start of the two-day conference (11/13).
Also In Global Health News: Nigerian Drug Institute Funding; Food Security, Climate Change; Heat-Stable, Nasal Vaccine Works In Mice; Task-Shifting In Swaziland; Bird Flu In Hong Kong
Nigerian Drug Research Institute Halts Research Because Of Funding Shortfall Nigeria’s National Institute for Pharmaceutical Research and Development (NIPRD), which focuses on developing traditional herbal remedies into drug candidates,Â has had to discontinue research after the Nigerian health ministry did not provide the full amount of expected fundingÂ and a “key grant…
Tuberculosis deserves an effort as “substantial” as the one mounted against swine flu “to develop a new vaccine,” David McMurray, a TB expert at Texas A&M University System Health Science Center, writes in a Houston Chronicle opinion piece. “Since April, … nearly one million men, women and children have died from TB, compared to 4,200 who have died from H1N1 flu globally. Why didn’t you see any headlines? Because 98 percent of the nearly two million people who die each year from TB live in the developing world, in places like Kenya … Yet TB continues to be a problem in [the U.S.] as well because in an age of globalization, germs cross borders without a passport,” McMurray writes.
New studies suggest that “[d]eveloping countries with limited access to advanced health-care facilities may be in for a rough ride with swine [H1N1] flu and even countries with high-tech ICUs may find themselves pushed to the limit as their hospitals struggle to save gravely ill H1N1 patients,” the Canadian Press reports. The studies, which compare outcomes among H1N1 patients admitted to intensive care units in Canada and Mexico,” show “the death rate in the latter was more than double that seen among Canadian patients. Just over 40 percent of critically ill Mexican patients succumbed to their illness by day 60, compared to 17.3 percent of Canadian patients by day 90.” The findings were reported online in the Journal of the American Medical Association (JAMA) on Monday.
Lancet Comment Examines Efforts To Subsidize ACTs A Lancet comment examines an Affordable Medicines Facility for malaria (AMFm) program to help countries procure subsidized artemisinin-based combination treatments (ACTs). The authors write though it is worth celebrating the recent advances in malaria prevention, “these successes cannot hide the fact that close…
As countries around the world roll out H1N1 (swine flu) virus vaccine campaigns, the Atlantic examines, “[W]hat if everything we think we know about fighting influenza is wrong?”
About 100 low- and middle-income countries could receive donated shipments of the H1N1 (swine flu) vaccine as early as November, Marie-Paule Kieny, of the WHO, told journalists Monday, Agence France-Presse reports. “Dozens of millions of doses are being lined up following offers from pharmaceutical companies,” including Sanofi-Aventis, GlaxoSmithKline and MedImmune, as well as a coalition of developed nations “that have pledged to release 10 percent of their vaccine purchases for poor nations,” the news service writes (10/12).
The WHO concluded a three-day meeting on H1N1 (swine flu) in Washington, D.C., on Friday, where health experts issued recommendations that patients with symptoms of H1N1 and pneumonia be treated quickly with antivirals, even before the results of H1N1 tests are complete, the San Francisco Chronicle blog, “ChronRX” reports.